Henry Ford derives profits from diversity

Henry Ford Health System has just one strategy: vertical integration. The Detroit system spent the 1980s collecting healthcare businesses to balance its full-service delivery system, and now it's filling in the gaps and streamlining operations.     

Henry Ford Health System's web site has comprehensive information

Henry Ford Health System, Detroit, has won awards for its web site. We bring you some of the highlights of this comprehensive, attractive site.     

Detroit's Henry Ford Health System awarded Foster G. McGaw Prize

Henry Ford Health System, Detroit, is named winner of the prestigious Foster G. McGaw Prize for excellence in community service. The organization received 100,000 dollars from the sponsors, the American Hospital Association, The Baxter International Foundation and the Cardinal Health Foundation.     

Human growth hormone treatment: Henry Ford Hospital experience 1964-1990

Treatment with human growth hormone (GH) at Henry Ford Hospital began in 1964 and has included 145 patients. A total of 68 patients were treated with extracted hormone and 77 with recombinant GH. The appearance of Creutzfeldt-Jakob disease, now five cases worldwide, in patients treated with extracted hormone abruptly stopped its use in the United States. The development of recombinant GH in 1985 has resulted in greater availability of treatment. Diagnostic criteria are now more liberal and certain patients without GH deficiency, i.e., those with the Turner syndrome, are now being successfully treated with GH. GH is expensive and its inappropriate use would have a major impact on health care costs. Indications for its use are not yet fully elucidated.